RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II trial

被引：1
|
作者：
Johnson, M. L. [1 ]
Langdon, R. [2 ]
Ellison, D. [3 ]
Spira, A. [4 ]
Amin, H. [5 ]
Castine, M. [6 ]
Daniel, D. B. [7 ]
Sohoni, S. [8 ]
Chen, Y-C. [8 ]
Hayes, J. [8 ]
Mu, Y. [8 ]
Masciari, S. [9 ]
Wang, X. [8 ]
Toya, S. [10 ]
机构：
[1] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[2] Nebraska Canc Specialists, Omaha, NE USA
[3] Charleston Oncol PA, Charleston, SC USA
[4] Virginia Canc Specialists Res Inst, Fairfax, VA USA
[5] Boca Raton Clin Res Associates Inc, Plantation, FL USA
[6] Hematol Oncol Clin, Baton Rouge, LA USA
[7] Sarah Cannon Res Inst Tennessee Oncol, Chattanooga, TN USA
[8] Revolut Med, Redwood City, CA USA
[9] Sanofi, Cambridge, MA USA
[10] GenHarp Clin Solut LLC, Evergreen Pk, IL USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
76TiP
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [1] RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial
    Johnson, M. L.
    Langdon, R.
    Ellison, D.
    Spira, A.
    Amin, H.
    Castine, M.
    Daniel, D.
    Larson, T.
    Sohoni, S.
    Chen, Y. C.
    Hayes, J.
    Yang, L.
    Masciari, S.
    Wang, X.
    Toya, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S454 - S455
  • [2] SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation
    Lee, C.
    Pavlakis, N.
    Zhou, D. D. -X.
    Brown, C.
    Hughes, B. G. M.
    Yip, S.
    Bray, V. J.
    Daley, F. T.
    Roberts-Thomson, R.
    Cummins, M. M.
    John, T.
    Solomon, B. J.
    Mitchell, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S361 - S362
  • [3] A Phase I Clinical Trial of Carfilzomib in Combination with Sotorasib in Patients with KRASG12C Mutated NSCLC
    Malhotra, J.
    Li, X.
    Palmer, J.
    Synold, T. W.
    Mohanty, A.
    Singhal, S.
    Kulkarni, P.
    Salgia, R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S659 - S660
  • [4] Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors
    Falchook, G.
    Li, B. T.
    Marrone, K. A.
    Bestvina, C. M.
    Langer, C. J.
    Krauss, J. C.
    Strickler, J. H.
    Meloni, A.
    Dai, T.
    Varrieur, T.
    Hong, D. S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S8 - S8
  • [5] Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 Studies
    Nagase, Mario
    Houk, Brett
    Vuu, Irene
    Cardona, Panli
    Dutta, Sandeep
    Lin, Chih-Wei
    AAPS JOURNAL, 2025, 27 (01):
  • [6] Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).
    Hong, David S.
    Strickler, John H.
    Fakih, Marwan
    Falchook, Gerald Steven
    Li, Bob T.
    Durm, Greg Andrew
    Burns, Timothy F.
    Ramalingam, Suresh S.
    Goldberg, Sarah B.
    Frank, Richard C.
    Marrone, Kristen
    Shu, Catherine A.
    Gandara, David R.
    Soman, Neelesh
    Henary, Haby Adel
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)
    Hong, David S.
    Yaeger, Rona
    Kuboki, Yasutoshi
    Masuishi, Toshiki
    Barve, Minal A.
    Falchook, Gerald Steven
    Govindan, Ramaswamy
    Sohal, Davendra
    Kasi, Pashtoon Murtaza
    Burns, Timothy F.
    Langer, Corey J.
    Puri, Sonam
    Chan, Emily
    Jafarinasabian, Pegah
    Ngarmchamnanrith, Gataree
    Rehn, Marko
    Tran, Qui
    Gandara, David R.
    Strickler, John H.
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
    Fakih, Marwan G.
    Kopetz, Scott
    Kuboki, Yasutoshi
    Kim, Tae Won
    Munster, Pamela N.
    Krauss, John C.
    Falchook, Gerald S.
    Han, Sae-Won
    Heinemann, Volker
    Muro, Kei
    Strickler, John H.
    Hong, David S.
    Denlinger, Crystal S.
    Girotto, Gustavo
    Lee, Myung-Ah
    Henary, Haby
    Tran, Qui
    Park, Joseph K.
    Ngarmchamnanrith, Gataree
    Prenen, Hans
    Price, Timothy J.
    LANCET ONCOLOGY, 2022, 23 (01): : 115 - 124
  • [9] A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation.
    Price, Timothy
    Grewal, Jaspreet
    Abed, Afaf
    Moore, Melissa
    Yeh, Yu-Min
    Gadgeel, Shirish
    Richardson, Gary
    Underhill, Craig
    Ganju, Vinod
    Lee, Keun-Wook
    Huh, Seok Jae
    Kim, Sang-We
    Yang, Chih-Hsin
    Chen, Yuh-Min
    Xiang, Ziyong
    Shi, Zhe
    Wang, Yaolin
    Zhang, Ling
    Millward, Michael
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
    Ernst, S. M.
    de Bruijn, P.
    van der Horst, T. E.
    Paats, M. S.
    Aerts, J. G.
    Mathijssen, R. H.
    Koolen, S. L.
    Dingemans, A-M. C.
    ANNALS OF ONCOLOGY, 2023, 34
12345